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Spread of
Extensively 
Drug-resistant
Tuberculosis
To the Editor: An emergency
has been declared in KwaZulu Natal,
South Africa, where an outbreak of 53
cases of a highly lethal form of tuber-
culosis (TB) has occurred (1,2). This
outbreak was caused by an extensive-
ly drug-resistant TB (XDR TB) strain.
XDR TB is defined as TB caused
by  Mycobacterium tuberculosis iso-
lates resistant to isoniazid and
rifampicin plus any fluoroquinolone
and >1 of the 3 injectable second-line
drugs (3). XDR TB may be consid-
ered an emerging disease but not a
new disease. Nosocomial outbreaks of
multidrug-resistant TB (MDR TB)
occurred in Spain at the height of the
HIV epidemic, when 49 TB cases
were reported in an HIV ward in
Madrid from 1991 through 1995
(4,5). Molecular epidemiology found
that a particular strain caused 16 cases
in another hospital in Madrid in
1993–1995 (6) and 31 cases in a hos-
pital in Malaga in 1995–1998 (7,8). In
total, 22 hospitals from 6 different
regions of Spain were affected by this
outbreak, which included at least 114
cases, caused by an M. bovis XDR
strain (B strain) belonging to the M.
tuberculosis complex. The patients
included 1 from the Netherlands (8)
and another from Canada (9).
The strain responsible for the
1991–1995 outbreak in Spain fits the
XDR TB case definition; it was resist-
ant to the 5 first-line drugs, as well as
to ofloxacin, aminosalicylic acid,
cycloserine, ethionamide, capre-
omycin, amikacin, and clar-
ithromycin. Isolates were tested for
drug susceptibility by the Canetti
method on Lowenstein-Jensen medi-
um supplemented with isoniazid,
rifampicin, ethambutol, streptomycin,
amikacin, and pyrazinamide (6). The
isolates were also tested on 7H10
Middlebrook agar for susceptibility to
aminosalicylic acid, ethionamide,
capreomycin, clarithromycin, and
ofloxacin (6). No effective medical
treatment was available for these
patients. In 2 of the hospitals affected,
all patients died, with a short survival
time (median of 44 and 49.5 days for
the 2 hospitals) between diagnosis
and death (6,7). Ahigh rate of reinfec-
tion (45%) also was noted among
HIV-positive patients treated with
anti-TB drugs (7). As a result of this
outbreak, Spanish hospitals now
implement exhaustive control meas-
ures, such as maintaining respiratory
isolation units under negative pres-
sure; in addition, a national surveil-
lance network for MDR TB was set
up in Spain in 1998. From 1998
through 2003, we detected 22 new
cases of infection with this strain (10),
but no new cases have since been
reported to the national MDR TB
database.
Our experience indicates that the
implementation of more stringent
control measures and the use of new,
more effective treatments for HIV
infection can help to bring XDR TB
outbreaks under control in developed
countries. However, the outlook is
bleak for developing countries like
South Africa, in which coinfection
with HIV and a highly transmissible
and untreatable XDR TB strain could
amplify the TB problem to levels
unprecedented since the advent of
antimicrobial drugs. These countries
urgently require assistance with the
establishment of control measures and
the development of new drugs and
effective vaccines against TB.
Acknowledgments
We thank the contributing members
of the Spanish Working Group on MDR-
TB for assistance.
This work was supported in part by
Spanish Ministerio de Sanidad y Consumo
(FIS 03/0743 and FIS 06-1624) and
Centro Investigacion Biomedica en Red
Enfermedades Respiratorias (CIBERES)
CB06/06/0020.
Sofía Samper* and Carlos Martín†
*Hospital Universitario Miguel Servet,
Instituto Aragonés de Ciencias de la Salud,
Zaragoza, Spain; and †University of
Zaragoza, Zaragoza, Spain
References
1.  Gandhi NR, Moll A, Sturm AW, Pawinski
R, Govender T, Lalloo U, et al.
Extensively drug-resistant tuberculosis as
a cause of death in patients co-infected
with tuberculosis and HIV in a rural area
of South Africa. Lancet. 2006;368:
1575–80.
2.  Cohen J. Infectious disease. Extensively
drug-resistant TB gets foothold in South
Africa. Science. 2006;313:1554.
3. Centers for Disease Control and
Prevention. Revised definition of exten-
sively drug-resistant tuberculosis.
MMWR Morb Mortal Wkly Rep.
2006;55:1176.
4. Centers for Disease Control and
Prevention. Multidrug-resistant tubercu-
losis outbreak on an HIV ward—Madrid,
Spain, 1991–1995. MMWR Morb Mortal
Wkly Rep. 1996;45:330–3.
5.  Rullan JV, Herrera D, Cano R, Moreno V,
Godoy P, Peiro EF, et al. Nosocomial
transmission of multidrug-resistant
Mycobacterium tuberculosis in Spain.
Emerg Infect Dis. 1996;2:125–9.
6.  Guerrero A, Cobo J, Fortun J, Navas E,
Quereda C, Asensio A, et al. Nosocomial
transmission of Mycobacterium bovis
resistant to 11 drugs in people with
advanced HIV-1 infection. Lancet.
1997;350:1738–42.
7.  Rivero A, Marquez M, Santos J, Pinedo
A, Sanchez MA, Esteve A, et al. High rate
of tuberculosis reinfection during a noso-
comial outbreak of multidrug-resistant
tuberculosis caused by Mycobacterium
bovis strain B. Clin Infect Dis. 2001;32:
159–61.
8.  Samper S, Martin C, Pinedo A, Rivero A,
Blazquez J, Baquero F, et al.
Transmission between HIV-infected
patients of multidrug-resistant tuberculo-
sis caused by Mycobacterium bovis.
AIDS. 1997;11:1237–42.
9.  Long R, Nobert E, Chomyc S, van
Embden J, McNamee C, Duran RR, et al.
Transcontinental spread of multidrug-
resistant.  Mycobacterium bovis. Am J
Respir Crit Care Med. 1999;159:2014–7.LETTERS
10. Samper S, Iglesias MJ, Rabanaque MJ,
Gomez LI, Lafoz MC, Jimenez MS, et al.;
Spanish Working Group on MDR-TB.
Systematic molecular characterization of
multidrug-resistant Mycobacterium tuber-
culosis complex isolates from Spain. J
Clin Microbiol. 2005;43:1220–7.
Address for correspondence: Carlos Martin,
Grupo de Genetica de Micobacterias,
Departamento de Microbiologia, Medicina
Preventiva, y Salud Publica, Facultad de
Medicina, Universidad de Zaragoza, C/
Domingo Miral sn, 50009 Zaragoza, Spain;
email: carlos@unizar.es
Transfusion-
associated
Hepatitis E, France 
To the Editor: Hepatitis E virus
(HEV) is a leading cause of acute and
fulminant hepatitis in developing
countries (1). In industrialized coun-
tries, HEV seroprevalence rates of
0.4%–3% are common, and evidence
is mounting that autochthonous trans-
mission might account for a substan-
tial proportion of infections (1–3).
Whereas fecal-oral HEV transmission
is preponderant in developing coun-
tries, other routes have been demon-
strated in industrialized countries,
among them consumption of pork or
boar meat (1,4). Parenteral transmis-
sion was first suggested but not
demonstrated (5,6). Because viruses
cannot be fully inactivated in blood
products, HEV recently emerged as a
transfusion-transmitted pathogen,
with 6 reported cases, including 3 in
which comparative analysis of HEV
sequences from blood donor and
recipient was performed (7). We
describe what is, to our knowledge,
the first case in France and the first
case worldwide involving a child as
blood recipient.
A 7-year-old boy was examined
in June 2006; he had erythematous-
papulous skin and an increased level
of alanine aminotransferase (ALT, 796
IU/L) of 1 week’s duration. From
October 2005 to May 2006, he had
received several courses of combined
chemotherapy for a rhabdoid tumor in
his kidney. Therapy included carbo-
platin, cyclophosphamide, etoposide,
adriamycin, and vincristine, and,
because of the chemotherapy’s hema-
totoxicity, the patient required 22
transfusions of concentrated erythro-
cytes or platelets. Peak levels of ALT
and bilirubin were reached 4 weeks
after onset of hepatitis (2,001 IU/Land
49  µmol/L, respectively), and ALT
levels returned to normal range (8–45
IU/L) 6 weeks later. During a follow-
up examination, the boy’s prothrom-
bin index remained >80%, and clinical
signs mostly consisted of clinical jaun-
dice. HEV diagnosis was established
by detection in serum of HEVantibod-
ies (EIAgen Kits, Adaltis Develop-
ment Inc., Laval, Quebec, Canada)
and HEV RNA with in-house assays.
Other infectious or noninfectious
causes of acute hepatitis were exclud-
ed. HEV immunoglobulin M (IgM)
was weakly positive in June 2006
(optical density ratio = 1.6), then
strongly positive the next month (ratio
= 10.8); IgG remained negative. HEV
RNA was detected from serum sam-
ples collected in June 2006 by an in-
house real-time PCR that targeted the
open reading frame 2 region of the
HEV genome. Sequences of primers/
probe are as follows: HevMrsRT
fwd: 5′-AATTRATTTCGTCGGCY
GG-3′; HevMrsRTRev: 5′- ACW
GTCGGCTCGCCATTG-3′ ;
HevMrsFam: 5′-FAM-ACTCYCGC
CASGTYGTCTCA-TAMRA-3′.
Serum samples taken from 12 U
of blood products that the child
received during the 3-month period
before onset of hepatitis were tested
for HEV RNA; 1 sample was positive.
Concentrated erythrocytes (310 mL)
from this positive blood donation
were transfused to the child in May
2006, 4 weeks after collection and 6
weeks before acute hepatitis devel-
oped. HEV IgG and IgM antibodies
were not detected in the blood dona-
tion, which indicates that the blood
donation occurred during the pro-
dromic phase of HEV disease. HEV
nucleotide sequences from the blood
donor and recipient were identical.
Phylogenetic analysis showed that
they clustered together and were
closely related to genotype 3f, which
is prevalent in Europe (Figure [8]). 
The blood donor was a 24-year-
old man. He did not travel outside
metropolitan France for 8 months
before donating blood. Anti-HEV IgG
seroconversion was observed on a
serum sample collected 24 weeks
after blood donation, whereas anti-
HEV IgM and serum HEV RNA test-
ed negative. ALT levels were within
normal values at the time of blood
donation and 24 weeks later. No clin-
ical signs were reported at any time.
No other recipient received blood
products from this donor.
Our data show that HEV was
transmitted from 1 blood donor to the
recipient child. On the basis of retro-
spective HEV RNA detection, 6 other
transfusion-transmitted HEV infec-
tions, all involving adult blood recipi-
ents, have occurred in HEV-hyperen-
demic and industrialized countries
(7). Transfusion-transmitted HEV
strains belonged to different geno-
types/subtypes that corresponded to
those found in the same geographic
areas (Figure).
In France, neither HEV antibod-
ies nor HEV RNA are systematically
tested in blood donors, and blood
donations currently are not tested for
ALT. In the absence of systematic
HEV RNA testing, HEV diagnosis in
blood donations may be hampered by
HEVviremia before clinical onset and
anti-HEV seroconversion, the possi-
ble short persistence or absence of
HEV antibodies, and the high fre-
quency of subclinical infections
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